ABSTRACT
INTRODUCTION: The objetive of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey. MATERIAL AND METHODS: Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in this population. RESULTS: A total of 2,789 patients answered the survey, of which 28 had a diagnosis of uveitis associated with SAE. The majority (82%) were female and caucasian (82%), with a mean age of 48 years. The most frequent SAEs were Behçet's disease followed by sarcoidosis and systemic lupus erythematosus. 46% of the patients were receiving corticosteroid treatment at a mean prednisone dose of 11 mg/day. Regarding infection, 14 (50%) patients reported symptoms compatible with SARS-CoV-2 infection. RT-PCR was performed on the nasopharyngeal smear in two patients and in one of them (4%) it was positive. CONCLUSIONS: Both asymptomatic and symptomatic COVID-19 patients with ASD-associated UNI had received similar immunosuppressive treatment.
ABSTRACT
INTRODUCTION: The objective of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey. MATERIAL AND METHODS: Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in this population. RESULTS: A total of 2,789 patients answered the survey, of which 28 had a diagnosis of uveitis associated with SAE. The majority (82%) were female and caucasian (82%), with a mean age of 48 years. The most frequent SAEs were Behçet's disease followed by sarcoidosis and systemic lupus erythematosus. 46% of the patients were receiving corticosteroid treatment at a mean prednisone dose of 11 mg/day. Regarding infection, 14 (50%) patients reported symptoms compatible with SARS-CoV-2 infection. RT-PCR was performed on the nasopharyngeal smear in two patients and in one of them (4%) it was positive. CONCLUSIONS: Both asymptomatic and symptomatic COVID-19 patients with ASD-associated UNI had received similar immunosuppressive treatment.
Subject(s)
Autoimmune Diseases/complications , COVID-19/complications , Uveitis/etiology , Adult , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Self ReportABSTRACT
Introducción El objetivo de este estudio es conocer las características de la COVID-19 en pacientes con uveítis asociada a enfermedades autoinmunes sistémicas (EAS) mediante una encuesta telemática. Material y métodos La Sociedad Española de Medicina Interna por medio del Grupo de Trabajo de Enfermedades Autoinmunes realizó una encuesta telemática a pacientes con EAS para conocer las características de la COVID-19 en esta población. Resultados Un total de 2.789 pacientes contestaron la encuesta, de los que 28 tenían un diagnóstico de uveítis asociada a una EAS. La mayoría (82%) eran mujeres y caucásicas (82%), con una media de 48 años. Las EAS más frecuentes fueron la enfermedad de Behçet seguida de la sarcoidosis y del lupus eritematoso sistémico. El 46% de los pacientes estaban recibiendo tratamiento con corticoides a una dosis media de prednisona de 11mg/día. Respecto a la infección, 14 (50%) pacientes referían síntomas compatibles con infección por SARS-CoV-2. Se realizó RT-PCR en el frotis nasofaríngeo en dos pacientes y en uno de ellos (4%) fue positivo. Conclusiones Los pacientes con UNI asociada a EAS tanto los asintomáticos como los sintomáticos de COVID-19 habían recibido de forma similar tratamiento inmunosupresor (AU)
Introduction The objetive of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey. Material and methods Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in this population. Result a total of 2,789 patients answered the survey, of which 28 had a diagnosis of uveitis associated with SAE. The majority (82%) were female and caucasian (82%), with a mean age of 48 years. The most frequent SAEs were Behçet's disease followed by sarcoidosis and systemic lupus erythematosus. 46% of the patients were receiving corticosteroid treatment at a mean prednisone dose of 11mg/day. Regarding infection, 14 (50%) patients reported symptoms compatible with SARS-CoV-2 infection. RT-PCR was performed on the nasopharyngeal smear in two patients and in one of them (4%) it was positive. Conclusions Both asymptomatic and symptomatic COVID-19 patients with ASD-associated UNI had received similar immunosuppressive treatment (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Autoimmune Diseases/complications , Uveitis/complications , Coronavirus Infections/complications , Pneumonia, Viral/complications , Pandemics , Cross-Sectional Studies , Autoimmune Diseases/drug therapy , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapyABSTRACT
Clopidogrel is a thienopyridine-class antiplatelet drug commonly used in ischemic heart disease,cerebrovascular disease and peripheral artery disease.Liver toxicity due to this drug is very infrequent.We found 16 cases in the literature, and in only two of them liver biopsy was carried out. We report the case of a 78 year old patient with multiple conditions affected by severe toxic cholestatic hepatitis due to clopidogrel and the results of the liver biopsy performed. Hepatitis was resolved after discontinuing the drug.Based on the characteristics of this case and other previously published cases, we review the characteristics of toxic hepatitis due to clopidogrel and its diagnosis and treatment.
Subject(s)
Chemical and Drug Induced Liver Injury , Platelet Aggregation Inhibitors/adverse effects , Ticlopidine/analogs & derivatives , Clopidogrel , Coronary Artery Disease/drug therapy , Humans , Platelet Aggregation Inhibitors/therapeutic use , Ticlopidine/adverse effects , Ticlopidine/therapeutic useABSTRACT
El clopidogrel es un fármaco antiagregante de la familia de la tienopiridinas muy utilizado en pacientes con cardiopatía isquémica, ictus y arteriopatía periférica. La toxicidad hepática por este fármaco es muy infrecuente. En la bibliografía únicamente se han descrito 16 casos, y solo en dos de ellos se practicó una biopsia hepática. Se presenta el caso de un paciente de 78 años pluripatológico que presentó una hepatitis tóxica colestásica severa por este fármaco y los hallazgos de la biopsia hepática que se le realizó. El cuadro se resolvió tras la retirada del fármaco. En base a los hallazgos de nuestro caso y los de los casos previamente publicados se revisan las características de la hepatitis tóxica por clopidogrel y su manejo diagnóstico y terapéutico (AU)
Clopidogrel is a thienopyridine-class antiplatelet drug commonly used in ischemic heart disease, cerebrovascular disease and peripheral artery disease. Liver toxicity due to this drug is very infrequent. We found 16 cases in the literature, and in only two of them liver biopsy was carried out. We report the case of a 78 year old patient with multiple conditions affected by severe toxic cholestatic hepatitis due to clopidogrel and the results of the liver biopsy performed. Hepatitis was resolved after discontinuing the drug. Based on the characteristics of this case and other previously published cases, we review the characteristics of toxic hepatitis due to clopidogrel and its diagnosis and treatment (AU)
Subject(s)
Humans , Male , Middle Aged , Chronic Disease/drug therapy , Hepatitis/complications , Platelet Aggregation Inhibitors/adverse effects , Biopsy , Drug-Related Side Effects and Adverse Reactions/complications , Cholestasis/chemically induced , Cholestasis/complications , Metronidazole/therapeutic use , Liver/pathology , Liver , Liver/surgery , Fatty Liver/chemically induced , Fatty Liver/complicationsSubject(s)
Hemopneumothorax , Adolescent , Female , Hemopneumothorax/diagnosis , Hemopneumothorax/therapy , HumansABSTRACT
No disponible
Subject(s)
Humans , Female , Adolescent , Hemopneumothorax/etiology , Thoracoscopy , Drainage , Radiography, ThoracicABSTRACT
No disponible
Subject(s)
Female , Adolescent , Humans , Insulinoma/complications , Insulinoma/diagnosis , Myoclonic Epilepsy, Juvenile/complicationsABSTRACT
No disponible
Subject(s)
Male , Aged , Aged, 80 and over , Humans , Enterobacteriaceae Infections/diagnosis , Kluyvera , Respiratory Tract Infections/microbiology , Superinfection/microbiologyABSTRACT
No disponible
No disponible
Subject(s)
Middle Aged , Male , Humans , Treatment Outcome , Eosinophilia , Gastroenteritis , Glucocorticoids , Gastric MucosaABSTRACT
No disponible
Subject(s)
Aged , Male , Humans , Shoulder , Arthritis, Infectious , BrucellosisABSTRACT
An allogeneic transplantation of CD34(+)-selected cells from peripheral blood (allo-PBT/CD34(+)) from HLA-identical sibling donors was performed in 50 adult patients with acute myeloid leukemia in first complete remission (AML CR1) (n = 29), myelodysplastic syndrome (MDS) (n = 4), or chronic myeloid leukemia in first chronic phase (CML CP1) (n = 17). Clinical results were compared to a concurrent group of 50 patients transplanted with unmodified peripheral blood progenitor cells (allo-PBT), matched for age, diagnosis, and disease stage. The median follow-up period was 29 months (range 1-69). The actuarial probability of developing acute GVHD clinical grade II to IV was 16% (95%CI: 6-26) for the allo-PBT/CD34(+) group and 41% (95%CI: 29-57) for the allo-PBT group (P = 0.002). The actuarial probability of developing extensive chronic GVHD was 22% (95%CI: 8-36) for the allo-PBT/CD34(+) group and 47% (95%CI: 31-63) for the allo-PBT group (P = 0.02). Recipients of allo-PBT/CD34(+) had less toxicity associated with the transplant and better Karnofsky index at the last follow-up. For AML/MDS patients, the actuarial probability of disease-free survival (DFS) for recipients of allo-PBT/CD34(+) and allo-PBT was 65% (95%CI: 45-85) vs43% (95%CI: 28-58) (P = 0.05), respectively. These data provide a rationale for a randomised trial of allo-PBT/CD34(+) vs allo-PBT in AML/MDS patients in early stage of the disease.
Subject(s)
Anemia, Refractory, with Excess of Blasts/therapy , Antigens, CD34/biosynthesis , Blood Transfusion , Hematopoietic Stem Cell Transplantation , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Leukemia, Myeloid, Acute/therapy , Acute Disease , Adolescent , Adult , Aged , Anemia, Refractory, with Excess of Blasts/mortality , Antigens, CD34/blood , Blood Transfusion/mortality , Case-Control Studies , Chronic Disease , Disease-Free Survival , Female , Graft vs Host Disease/epidemiology , Graft vs Host Disease/mortality , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Recurrence , Transplantation, HomologousABSTRACT
No disponible
Subject(s)
Aged , Female , Humans , Mesothelioma , Diagnosis, Differential , Pleural NeoplasmsABSTRACT
This study analyzed the characteristics of 257 HLA-identical sibling transplants of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells depleted of T cells by CD34(+) positive selection (allo-PBT/CD34(+)) for their effect on the incidence of graft failure. Twenty-four patients developed graft failure (actuarial probability, 11%; 95% confidence interval, 7.1-14. 9). Prognostic factors considered were sex and age of donor and recipient, donor-recipient blood group compatibility, diagnosis, disease status at transplant, conditioning regimen, cytomegalovirus serology, number of CD34(+) and CD3(+) cells infused, and cryopreservation. The major factor associated with graft failure was the number of CD3(+) cells in the inoculum. Twenty-three of 155 patients receiving a T-cell dose in the graft less than or equal to 0.2 x 10(6)/kg experienced graft failure, compared with only one of 102 patients receiving more than 0.2 x 10(6)/kg (actuarial probability 18% vs 1%, respectively; P =.0001). The actuarial probability of graft failure progressively increased as the number of CD3(+) cells in the graft decreased, which was determined by grouping the number of CD3(+) cells in quartiles (log-rank P =.03; log-rank for trend P =.003). In the multivariate analysis by the proportional hazard method, 2 covariates entered into regression at a significant level: CD3(+) cells less than or equal to 0.2 x 10(6)/kg (risk ratio = 17; P <.0001), and patients with chronic myelogenous leukemia (CML) conditioned with busulphan-based regimens (risk ratio = 4.8; P =.001). From these results it appears that the number of CD3(+) cells in the inoculum-with a threshold of 0.2 x 10(6)/kg or less-is the most critical factor in maintaining a sustained engraftment in allo-PBT/CD34(+) from HLA-identical siblings. In addition, for patients with CML receiving 0.2 x 10(6)/kg or less CD3(+) cells, total body irradiation might be better than busulphan-based regimens.
Subject(s)
Antigens, CD34/blood , CD3 Complex/blood , Graft Rejection/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Lymphocytes/immunology , Actuarial Analysis , Adolescent , Adult , Blood Donors , Cell Count , Female , Follow-Up Studies , Graft Rejection/blood , Graft Rejection/immunology , Hematologic Neoplasms/complications , Hematologic Neoplasms/diagnosis , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/standards , Histocompatibility , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Lymphocyte Depletion/standards , Male , Middle Aged , Multivariate Analysis , Nuclear Family , Prognosis , Transplantation, Homologous/adverse effects , Transplantation, Homologous/immunologySubject(s)
Mesothelioma/diagnosis , Pleural Neoplasms/diagnosis , Aged , Diagnosis, Differential , Female , HumansABSTRACT
OBJECTIVE: To ascertain the general pattern of hospital antimicrobial use, costs, and adequacy of treatment in the department of internal medicine of a general hospital. MATERIAL AND METHODS: A prevalence study was carried out and all department beds were visited. Every patient who was being treated with antimicrobials during or 24 hours prior to the visit was selected for the study. Treatment was considered adequate when indication, selected drug, dosage, and treatment duration were all adequate. When considering costs, only the price of the antimicrobials was evaluated. RESULTS: We identify 173 hospitalized patients, 79 (45.6%) of them were treated with 96 antimicrobial agents. The prevalence of community-acquired and hospital-acquired infections was 39.3% and 8.1%, respectively. Empirical use amounted to 77%. Overall, b-lactams antibiotics were the most frequently used (63.5%). In 22 (27.8%) patients treatment was judged inadequate, the most frequent error being an excessive duration (17.8%). The daily spending on antimicrobials was 187,750 ptas., representing 1,085 ptas. per hospitalized patient and day. CONCLUSIONS: A high percentage of hospitalized patients receive treatment with antimicrobial drugs. Because of the low rate of antimicrobials with a specific indication, the long antibiotic course duration, the incorrect drug choice, and even more the antimicrobial prescription in non-infected patients, strategies to improve the quality of antimicrobial use are clearly required